Oncology / Haematology

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Trial Name: THOR  PI: Dr Emma Beardsley

Who can take part:

  • Patients with Histologic demonstration of transitional cell carcinoma of the urothelium.
  • Patients with Metastatic or surgically unresectable urothelial cancer
  • Patients must meet appropriate molecular eligibility criteria as determined by a Central Laboratory – Tumors must have at least 1 of the following translocations: FGFR2-BICC1, FGFR2-CASP7, FGFR3-TACC3, FGFR3-BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.

Exclusion criteria:

  • Patients with symptomatic central nervous system metastases.
  • Received prior FGFR inhibitor treatment.
  • Patients with a history of uncontrolled cardiovascular disease

For further information please contact Judi Clarke – 03 9784 8301

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4